Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer - 04/09/21
Poly-ADP-ribose polymerase inhibitors (iPARP) are a new class of targeted therapy which block the DNA repair mechanisms of cancer cells causing their apoptosis. They are mainly used in ovarian cancers to prevent a recurrence. The most common side effects are nausea and fatigue; the most serious are blood toxicities. Prescribed over several months, supportive care is essential to improve quality of life and consequently compliance with iPARPs. In our experience, the use of homeopathy and of ultra-high dilutions of iPARP, reduces side effects and is a great help to patients. The lack of drug interactions makes it possible for them to be used safely. The low cost and very good tolerance of this supportive treatment make it very acceptable to patients. Preliminary clinical studies should be carried out to confirm our favourable clinical impression.Le texte complet de cet article est disponible en PDF.
Keywords : Hetero-isotherapy, Homeopathy, Niraparib, Olaparib, Ovarian cancer, Rucaparib, Talazoparib
Vol 12 - N° 3P. e36-e42 - septembre 2021 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?